Kiora Pharmaceuticals (KPRX) Liabilities and Shareholders Equity (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $21.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 37.6% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.3 million (down 28.39% YoY) and the FY2025 annual result came in at $24.3 million, down 33.52% from the prior year.
• Liabilities and Shareholders Equity retreated to $21.2 million in Q1 2026, from $24.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $42.4 million in Q1 2024 to a low of $13.7 million in Q4 2023.
• A 5-year average of $25.6 million and a median of $21.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 166.08% — and 2026, when it sank 37.6%.
• Tracing KPRX's Liabilities and Shareholders Equity over 5 years: stood at $18.7 million in 2022, then fell by 26.59% to $13.7 million in 2023, then soared by 166.08% to $36.5 million in 2024, then sank by 33.52% to $24.3 million in 2025, then slipped by 12.48% to $21.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $21.2 million (Q1 2026), $24.3 million (Q4 2025), and $29.9 million (Q3 2025), per Business Quant data.